A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

Neuron

Volumn 76, Issue 5, 2012, Pages 908-920

  DeMattos, Ronald B ^a   Lu, Jirong ^a   Tang, Ying ^a   Racke, Margaret M ^a   DeLong, Cindy A ^a   Tzaferis, John A ^a   Hole, Justin T ^a   Forster, Beth M ^a   McDonnell, Peter C ^a   Liu, Feng ^a   Kinley, Robert D ^a   Jordan, William H ^a   Hutton, Michael L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMORRHAGE; HIPPOCAMPUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID;

EID: 84872144291     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2012.10.029     Document Type: Article

References (54)

1. Adolfsson O., Pihlgren M., Toni N., Varisco Y., Buccarello A.L., Antoniello K., Lohmann S., Piorkowska K., Gafner V., Atwal J.K., et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J. Neurosci. 2012, 32:9677-9689.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
3. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA 2003, 100:2023-2028.
4. Bibl M., Gallus M., Welge V., Lehmann S., Sparbier K., Esselmann H., Wiltfang J. Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides. Proteomics Clin. Appl. 2012, 6:163-169.
5. Black R.S., Sperling R.A., Safirstein B., Motter R.N., Pallay A., Nichols A., Grundman M. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2010, 24:198-203.
6. Boche D., Zotova E., Weller R.O., Love S., Neal J.W., Pickering R.M., Wilkinson D., Holmes C., Nicoll J.A. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310.
7. Bohrmann B., Baumann K., Benz J., Gerber F., Huber W., Knoflach F., Messer J., Oroszlan K., Rauchenberger R., Richter W.F., et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 2012, 28:49-69.
8. Chelius D., Jing K., Lueras A., Rehder D.S., Dillon T.M., Vizel A., Rajan R.S., Li T., Treuheit M.J., Bondarenko P.V. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal. Chem. 2006, 78:2370-2376.
9. Cynis H., Schilling S., Bodnár M., Hoffmann T., Heiser U., Saido T.C., Demuth H.U. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta 2006, 1764:1618-1625.
10. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 2001, 22:721-727.
11. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma/knock-out mice. J. Neurosci. 2003, 23:8532-8538.
12. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001, 98:8850-8855.
13. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., Holtzman D.M. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 2002, 81:229-236.
14. Esler W.P., Stimson E.R., Mantyh P.W., Maggio J.E. Deposition of soluble amyloid-beta onto amyloid templates: with application for the identification of amyloid fibril extension inhibitors. Methods Enzymol. 1999, 309:350-374.
15. Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., et al.). Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012, 8:261-271.
16. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
17. Giedraitis V., Sundelöf J., Irizarry M.C., Gårevik N., Hyman B.T., Wahlund L.O., Ingelsson M., Lannfelt L. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci. Lett. 2007, 427:127-131.
18. Golde T.E. Alzheimer disease therapy: can the amyloid cascade be halted?. J. Clin. Invest. 2003, 111:11-18.
19. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
20. Hong S., Quintero-Monzon O., Ostaszewski B.L., Podlisny D.R., Cavanaugh W.T., Yang T., Holtzman D.M., Cirrito J.R., Selkoe D.J. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. J. Neurosci. 2011, 31:15861-15869.
21. Iwatsubo T., Saido T.C., Mann D.M., Lee V.M., Trojanowski J.Q. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol. 1996, 149:1823-1830.
22. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
23. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 1997, 94:1550-1555.
24. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA 2009, 106:4012-4017.
25. Kuo Y.M., Emmerling M.R., Woods A.S., Cotter R.J., Roher A.E. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun. 1997, 237:188-191.
26. La Porte S.L., Bollini S.S., Lanz T.A., Abdiche Y.N., Rusnak A.S., Ho W.H., Kobayashi D., Harrabi O., Pappas D., Mina E.W., et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Bio. 2011, 421:525-536.
27. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S.G., Black R.S., Schenk D., Seubert P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 2005, 58:430-435.
28. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., Golde T.E. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2006, 116:193-201.
29. Mehta P.D., Pirttila T., Patrick B.A., Barshatzky M., Mehta S.P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 2001, 304:102-106.
30. Morris J.C., Price J.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 2001, 17:101-118.
31. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
32. Ossenkoppele R., Tolboom N., Foster-Dingley J.C., Adriaanse S.F., Boellaard R., Yaqub M., Windhorst A.D., Barkhof F., Lammertsma A.A., Scheltens P., et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur. J. Nucl. Med. Mol. Imaging 2012, 39:990-1000.
33. Ostrowitzki S., Deptula D., Thurfjell L., Barkhof F., Bohrmann B., Brooks D.J., Klunk W.E., Ashford E., Yoo K., Xu Z.X., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 2012, 69:198-207.
34. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
35. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
36. Pul R., Dodel R., Stangel M. Antibody-based therapy in Alzheimer's disease. Expert Opin. Biol. Ther. 2011, 11:343-357.
37. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 2005, 25:629-636.
38. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
39. Saido T.C. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 1998, 19(1, Suppl):S69-S75.
40. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
41. Saido T.C., Yamao-Harigaya W., Iwatsubo T., Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 1996, 215:173-176.
42. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
43. Schilling S., Lauber T., Schaupp M., Manhart S., Scheel E., Böhm G., Demuth H.U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45:12393-12399.
44. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med. 2008, 14:1106-1111.
45. Schlenzig D., Manhart S., Cinar Y., Kleinschmidt M., Hause G., Willbold D., Funke S.A., Schilling S., Demuth H.U. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 2009, 48:7072-7078.
46. Schroeter S., Khan K., Barbour R., Doan M., Chen M., Guido T., Gill D., Basi G., Schenk D., Seubert P., et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 2008, 28:6787-6793.
47. Sperling R.A., Jack C.R., Black S.E., Frosch M.P., Greenberg S.M., Hyman B.T., Scheltens P., Carrillo M.C., Thies W., Bednar M.M., et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011, 7:367-385.
48. Tseng B.P., Esler W.P., Clish C.B., Stimson E.R., Ghilardi J.R., Vinters H.V., Mantyh P.W., Lee J.P., Maggio J.E. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry 1999, 38:10424-10431.
49. Villemagne V.L., Pike K.E., Chételat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
50. Wang A., Das P., Switzer R.C., Golde T.E., Jankowsky J.L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 2011, 31:4124-4136.
51. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
52. Winkler D.T., Bondolfi L., Herzig M.C., Jann L., Calhoun M.E., Wiederhold K.H., Tolnay M., Staufenbiel M., Jucker M. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 2001, 21:1619-1627.
53. Yamada K., Yabuki C., Seubert P., Schenk D., Hori Y., Ohtsuki S., Terasaki T., Hashimoto T., Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 2009, 29:11393-11398.
54. Yates P.A., Sirisriro R., Villemagne V.L., Farquharson S., Masters C.L., Rowe C.C. Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease. Neurology 2011, 77:48-54. AIBL Research Group.